Results of a phase III trial, the Palbociclib CoLlaborative Adjuvant Study (PALLAS), presented at the 2021 San Antonio Breast Cancer Symposium (SABCS), December 7-10, 2021, "does not show significant improvements in survival endpoints for the addition of Palbociclib to adjuvant endocrine therapy over endocrine therapy alone in patients with early hormone receptor-positive, HER-2 negative breast cancer." Further, the trial unveiled that nearly half (44.9%) of patients were not able to complete the full 2 years of Palbociclib treatment due to neutropenia.
To read more about the results of this trial, click here.
Study mentioned: Gnant M, Dueck AC, Frantal S, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). JCO; Published online 7 December 2021. DOI: 10.1200/JCO.21.02554
No comments:
Post a Comment